Company intelligence / Profile preview

Novo Nordisk Pharmatech

Køge, Denmark

Ownership: Private
Employees: ~250
Development stage: Other

Overview

Novo Nordisk Pharmatech is a leading global supplier of high-quality ingredients for the pharmaceutical and biopharmaceutical industries. As a wholly-owned subsidiary of Novo Nordisk, the company specializes in the manufacturing of pharmaceutical-grade Quaternary Ammonium Compounds (Quats) and Recombinant Insulin. Their products are essential components in cell culture media and purification processes for the production of vaccines, monoclonal antibodies, and other biologics. Operating under stringent GMP standards, the company provides critical raw materials that ensure the safety and efficacy of life-saving medicines worldwide.

Modalities: Monoclonal antibodyVaccineRecombinant proteinCell therapyGene therapy
Industry: Chemicals & Materials

Beyond the preview

Go deeper on Novo Nordisk Pharmatech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novo Nordisk Pharmatech.

Explore the full profile